Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about treatment/resistant depression
Recent news which mentions treatment/resistant depression
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Tickers
ATAI
Tags
ATAI
VLS/01
Srinivas Rao
From
Benzinga
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
July 23, 2024
Tickers
JNJ
NEWS
Tags
News
TDR
ketamine depression
From
Benzinga
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
April 26, 2024
Tickers
NEWS
Tags
Market News
Cannabis
Benzinga
From
Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
March 28, 2024
Tickers
ATAI
NEWS
Tags
Benzinga
Psychedelic/Assisted Therapies
Cannabis
From
Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
Tags
Management
CMPS
COMP360
From
Benzinga
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
November 15, 2023
Tickers
AWKNF
CMPS
Tags
Psilocybin program
Benzinga
Penny Stocks
From
Benzinga
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
October 03, 2023
Tickers
ATAI
Tags
Psychedelics
treatment/resistant depression
Cannabis
From
Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
September 06, 2023
Tickers
CMPS
Tags
Small Cap
Rumors
Psychedelics
From
Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
August 24, 2023
Tickers
GHRS
Tags
Markets
Guidance
Management
From
Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
Tickers
CMPS
Tags
Small Cap
Psychedelics
treatment/resistant depression
From
Benzinga
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
July 05, 2023
Tickers
ATAI
CMPS
HTGC
Tags
News
ATAI
HTGC
From
Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
May 30, 2023
Tickers
CMPS
NUMIF
Tags
Small Cap
Psychedelics
treatment/resistant depression
From
Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
May 11, 2023
Tickers
GHRS
Tags
Markets
Guidance
General
From
Benzinga
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
May 04, 2023
Tags
News
General
BPL/003
From
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
Tickers
ATAI
CMPS
IGXT
Tags
ATAI
IGXT
CMPS
From
Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 12, 2022
Tickers
CMPS
Tags
Cannabis
Market News
Benzinga
From
Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 09, 2022
Tickers
CMPS
Tags
Market News
Cannabis
Psilocybin program
From
Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
November 16, 2022
Tickers
CMPS
Tags
Markets
News
CMPS
From
Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
November 02, 2022
Tags
Lusaris Therapeutics
Catalent
News
From
Benzinga
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
October 05, 2022
Tickers
ATAI
Tags
ATAI Life Sciences
Small Cap
News
From
Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
July 28, 2022
Tickers
CMPS
Tags
COMP360
Markets
COMPASS Pathways PLC
From
Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
April 12, 2022
Tags
College London’s Centre for Psychedelic Research
Robin Carhart/Harris
Benzinga
From
Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
Tags
Positive and Negative Affect Schedule
Markets
Compass Pathways
From
Benzinga
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
November 16, 2021
Tickers
GHRS
Tags
5/MeO/DMT
Health Care
Small Business
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.